GE-HEALTHCARE
1.3.2023 08:01:54 CET | Business Wire | Press release
GE HealthCare has today announced, at the European Congress of Radiology (ECR) in Vienna, Austria, the completion of Phase I subject recruitment in its early clinical development program for a first-of-its-kind manganese-based macrocyclic magnetic resonance imaging (MRI) contrast agent. Typically, MRI agents – used to enhance visualization of abnormal structures or lesions and to aid differentiation between healthy and pathological tissue – are gadolinium-based. This manganese-based agent could broaden GE HealthCare’s portfolio of MRI contrast agents available to radiologists, providing a potential alternative in light of perceived concerns relating to gadolinium retention.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230228006355/en/
GE HealthCare is innovating in contrast media (Photo: Business Wire)
The macrocyclic, extra-cellular – or general-purpose – manganese-based contrast agent has comparable relaxivity - the ability of a contrast agent to enhance signal intensity during an MRI scan - and is expected to be diagnostically similar to current gadolinium-based contrast agents (GBCAs). Unlike gadolinium, manganese is endogenous, meaning that it is a trace element that is naturally occurring in and efficiently eliminated from the body. Along with its magnetic properties, this makes a manganese-based agent a viable alternative to gadolinium. In addition, a non-gadolinium agent could help limit the potential impact of post-patient excreted gadolinium in the environment.
The clinical trial, based at the clinical research unit at the Oslo University Hospital, Rikshospitalet, Norway, and overseen by Lead Investigator, Hasse K. Zaré, aims to investigate the safety profile and how this injectable manganese contrast agent is eliminated from the body in healthy volunteers. Previous manganese-based MRI agents have been reliant on a ‘free manganese’ release mechanism for their imaging efficacy. This novel investigational agent is tightly bound to the chelate, in a macrocyclic cage-like structure, so it is rapidly eliminated from - rather than actively released into - the body.
Dr Paul Evans, Head of Global R&D at GE HealthCare’s Pharmaceutical Diagnostics unit, said: “For many years we’ve been committed to investing in, and bringing to market, products to help solve some of radiology’s biggest challenges and unmet needs. This manganese-based MRI agent is one of a number of novel agents we have at various stages of development in our innovation pipeline, all of which aim to give practitioners more choice in delivering precision care for their patients.”
GE HealthCare’s Pharmaceutical Diagnostics unit is a global leader in imaging agents used to support around 100 million procedures per year globally, equivalent to three patient procedures every second. For more than 40 years, GE imaging agents have been routinely used across MRI, X-ray/CT and ultrasound to enhance clinical images and support diagnosis.
About GE HealthCare Technologies Inc.
GE HealthCare is a leading global medical technology, pharmaceutical diagnostics, and digital solutions innovator, dedicated to providing integrated solutions, services, and data analytics to make hospitals more efficient, clinicians more effective, therapies more precise, and patients healthier and happier. Serving patients and providers for more than 100 years, GE HealthCare is advancing personalized, connected, and compassionate care, while simplifying the patient’s journey across the care pathway. Together our Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics businesses help improve patient care from diagnosis, to therapy, to monitoring. We are a $18.3 billion business with 50,000 employees working to create a world where healthcare has no limits.
Follow us on Facebook, LinkedIn, Twitter, and Insights for the latest news, or visit our website www.gehealthcare.com for more information.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230228006355/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incode Acquires Identiq to Expand Its Privacy-First Architecture for Identity and Fraud Prevention25.6.2026 15:00:00 CEST | Press release
Extends its privacy-by-design architecture with Identiq’s patented cryptographic technology that enables organizations to share fraud signals without sharing sensitive data. Incode Technologies, a global leader in AI-powered identity verification and fraud prevention, today announced that it has completed the acquisition of Identiq, a company specializing in privacy-enhancing cryptographic solutions for peer-to-peer anti-fraud collaboration. Incode announced this acquisition as part of a $100 million commitment to advancing its original privacy-preserving identity infrastructure. The funds will be used to enhance on-device processing capabilities, continue R&D in privacy-enhancing technologies, and expand engineering resources and its global footprint. “We have always believed that privacy and fraud prevention are not a tradeoff, but part of the same problem, solved together or not at all,” said Ricardo Amper, Founder and CEO of Incode. “Identiq is the piece that enhances our Privacy b
Gurobi Introduces New Optimization Game Set in a Fast-Paced Coffee Shop25.6.2026 15:00:00 CEST | Press release
Gurobean, companion to the “Burrito Optimization Game” with 85,000+ plays, introduces advanced concepts like nonlinearity and uncertainty. Gurobi Optimization, LLC, the leader in decision intelligence technology, today announced the launch of Gurobean: The Coffee Optimization Game, a new educational game that brings nonlinearity, simulation, and decision-making under uncertainty to life. Following the success of the Burrito Optimization Game—which has been played over 85,000 times by learners across the world since its launch in 2022—Gurobean places players behind the counter of a virtual coffee shop, where they must make critical decisions around pricing, staffing, queue management, inventory levels, and more. The free, interactive game furthers Gurobi’s ongoing commitment to open education, teaching players: The value of mathematical optimization How quickly real-world decision problems become too complex to solve by trial and error How nonlinearity and uncertainty make outcomes hard
AllUnity and Zebec Deploy EURAU-Powered Employee Benefits and Enterprise Payment Solutions on Stellar25.6.2026 14:59:00 CEST | Press release
AllUnity and Zebec today announced the launch of an EURAU-based employee benefits and enterprise payments program on the Stellar network. The pilot program aims to expand payroll and workforce payments in AllUnity's regulated euro stablecoin across its ecosystem, including its major enterprise clients and partners. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260625883682/en/ Built on Stellar and powered by EURAU, AllUnity's regulated euro stablecoin, the program combines regulated digital currency with enterprise grade payroll and payments infrastructure purpose built for global value transfer. Employees participating in the pilot can receive benefits directly to digital wallets while accessing a growing range of spending, savings, and payment options through the Zebec platform. "Regulated stablecoins are increasingly moving from financial infrastructure to real world business applications," said Simon Babakhani, CEO of Z
2026 Esri User Conference to Focus on Creating a More Intelligent World with GIS25.6.2026 14:00:00 CEST | Press release
More Than 18,000 Attendees Expected for World's Largest GIS Conference in San Diego The 2026 Esri User Conference will be held from July 13 to 17 in San Diego, California. This year's theme is "GIS—Creating a more intelligent world." Jack Dangermond, president and founder of Esri, and Kristine Tompkins, president and cofounder of Tompkins Conservation, will be the keynote speakers in the Plenary Session. Esri, the global leader in geographic information system (GIS) technology, today announced speakers and the conference theme for the 2026 Esri User Conference. The conference will be held from July 13 to 17 at the San Diego Convention Center in San Diego, California. This year's theme of "GIS—Creating a more intelligent world" will emphasize how GIS turns the science of "where" into shared understanding and coordinated action—at the scale of communities, enterprises, and the planet. Kristine Tompkins, president and cofounder of Tompkins Conservation, will join Esri president Jack Dange
Copeland Releases FY2025 Global Impact Report Highlighting Energy Efficiency, Safety and Innovation Progress25.6.2026 14:00:00 CEST | Press release
Scope 1 and Scope 2 greenhouse gas emissions declined nearly 20%1Near-term reduction targets validated by the Science Based Targets InitiativeGlobal Total Recordable Incident Rate improved to 0.21, outperforming the industry average by over 90% Copeland, a global leader in compression technologies and controls solutions, has released its second annual Global Impact Report. The report highlights the company’s Fiscal Year 2025 (FY25) progress across environmental sustainability, workplace safety and community impact, guided by its Purpose, Performance and People pillars. Copeland has advanced its sustainability commitments through three strategic areas of focus: Performance-Driven Decarbonization: Copeland reduced Scope 1 and Scope 2 greenhouse gas emissions by 20% year-over-year, advancing toward its Science Based Targets initiative (SBTi)-validated goal of a 55% absolute reduction by FY33, using FY23 as a baseline.2 Renewable energy procurement and onsite solar generation accounted for
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom